Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for Perioperative Optimization in Obese Patients Pending Total Knee Replacement
NCT06807970Phase 1Active, not recruiting
- Sponsor
- The University of Hong Kong
- Start
- Sep 2025
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of semaglutide in knee osteoarthritis (OA) and obesity (2 arms), sponsored by The University of Hong Kong. Primary endpoints: Visual Analogue Scale and Analgesic consumption. Started Sep 2025; status: active, not recruiting.
02
Drugs
03
Conditions
knee osteoarthritis (OA)obesity
Beyond the preview
Go deeper on NCT06807970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06807970.